Authors: DENOTTER W EVERSE LA KLEIN WR RUTTEN VPGM STEWART R HILL G BALEMANS L STEERENBERG PA DOBROWOLSKI Z ZEMBALA M

Citation: W. Denotter et al., HOW TO PERFORM EFFECTIVE IL-2 THERAPY, European journal of cancer, 33, 1997, pp. 380-380

Authors: DENOTTER W EVERSE LA BERNSEN MR KLEIN WR RUTTEN VPGM STEWART R HILL G BALEMANS L STEERENBERG PA FISZERMALISZEWSKA L DOBROWOLSKI Z ZEMBALA M

Citation: W. Denotter et al., EFFECTIVE IL-2 THERAPY, European journal of cancer, 33, 1997, pp. 24-24

Authors: HERR I BALEMANS L BOHLER T WALCZAK H DEBATIN KM

Citation: I. Herr et al., MONITORING OF CD95 (APO-1 FAS) LIGAND EXPRESSION IN HUMAN T-CELLS BY QUANTITATIVE RT-PCR/, Cell death and differentiation, 3(3), 1996, pp. 299-305

Authors: HERR I BALEMANS L FRIESEN C DEBATIN KM

Citation: I. Herr et al., DEVELOPMENT OF A QUANTITATIVE RT-PCR FOR THE HUMAN APO-1 (FAS CD95) LIGAND AND MONITORING OF LIGAND EXPRESSION IN NORMAL AND MALIGNANT T-CELLS/, Blood, 86(10), 1995, pp. 639-639